It inhibits tumor growth by suppressing SphK1 activity, binding to S1P receptors, thus hindering tumor vasculature, enhancing reactive oxygen species (ROS) production, and elevating T‐lymphocyte levels in the body.[223, 224] Sonepcizumab, a monoclonal antibody against S1P, has demonstrated efficacy in curtailing tumor growth, invasion, and angiogenesis in various murine models of human cancer. The gene discussed is SPHK1; the disease is neoplasm.